)
Edge28 Aug 2026
Bigger, Sharper, IMAX: A Blockbuster Business
How IMAX turned an unscalable, large-screen format into the center of blockbuster filmmaking through cameras, projection, and remastering technology.
Klaria Pharma
Klaria Pharma (KLAR) investor relations material
Klaria Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Focus during Q2 2026 was on strengthening financial position and preparing for the launch of Sumatriptan Alginate Film in Europe.
Bridge financing of 25 MSEK secured in June 2026 to support liquidity and strategic alternatives.
Preparations for a rights issue of up to 148 MSEK announced after the period, with strong investor interest.
Ongoing business development with BDO and continued patent protection efforts for key products.
Financial highlights
Net sales for Q2 2026 were 0 TSEK (0 TSEK in Q2 2025); for H1 2026, 100 TSEK (8,985 TSEK in H1 2025).
R&D expenses for Q2 2026 were 4,414 TSEK (7,090 TSEK); for H1 2026, 9,328 TSEK (10,515 TSEK).
Profit after tax for Q2 2026 was -12,887 TSEK (-20,118 TSEK); for H1 2026, -21,542 TSEK (-21,710 TSEK).
Cash flow from operating activities for Q2 2026 was -14,792 TSEK (-2,319 TSEK); for H1 2026, -14,874 TSEK (-1,718 TSEK).
Cash and cash equivalents at June 30, 2026 were 8,468 TSEK (1,969 TSEK).
Outlook and guidance
Launch preparations for Sumatriptan Alginate Film in Europe are progressing, with cost reimbursement milestones expected soon.
Targeting 10-30% market share of the European Sumatriptan market, valued at approximately 1 billion SEK annually.
Anticipates stable royalty cash flow and milestone payments upon successful market entry.
Business development for additional licensing agreements outside Europe is ongoing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Klaria Pharma
- Major licensing deal and EU approval for lead product amid deepening losses and lower sales.KLAR
Q4 2024 - Sharp revenue decline and deepening losses as product launch preparations continue.KLARQ1 2026
- Net sales grew to 9.0 MSEK, losses narrowed, and key product launch preparations advanced.KLARQ4 2025
- No Q3 sales, deepening losses, but key financing and European launch prep for lead product.KLARQ3 2025
- H1 2025 saw higher sales, major financing, and preparations for a key European product launch.KLARQ2 2025
- Q3 loss narrowed as Klaria pivots to licensing after EU approval for its migraine film.KLARQ3 2024
- EU approval for Sumatriptan Alginate Film marks a pivotal step as Klaria seeks licensing deals.KLARQ2 2024
- Q1 2025 sales surged and losses narrowed as Klaria secured a key European licensing deal.KLARQ1 2025
Next Klaria Pharma earnings date
Q3 202626 Nov, 2026
Klaria Pharma
Next Klaria Pharma earnings date
Q3 202626 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage